Compare Stocks: SPRO, SIGA, SLGL, and ANTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$5.93	$4.81	$1.00 ▼ $6.91	$213.60M	-0.99	195,500 shs	124,474 shs
SIGA Siga Technologies	$3.05	$3.78	$3.01 ▼ $9.62	$219.14M	0.97	785,568 shs	677,625 shs
SLGL Sol-Gel Technologies	$88.00	$77.40	$13.50 ▼ $97.97	$247.28M	1.12	52,374 shs	46,380 shs
SPRO Spero Therapeutics	$1.26	$2.00	$1.08 ▼ $3.08	$72.95M	1.55	2.41 million shs	458,505 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	0.00%	+10.84%	+31.78%	+25.64%	+454.21%
SIGA Siga Technologies	0.00%	-6.73%	-15.04%	-32.97%	-65.96%
SLGL Sol-Gel Technologies	0.00%	+6.99%	+19.00%	+25.75%	+450.34%
SPRO Spero Therapeutics	0.00%	+7.69%	-40.00%	-50.59%	-42.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$5.93	$4.81	$1.00 ▼ $6.91	$213.60M	-0.99	195,500 shs	124,474 shs
SIGA Siga Technologies	$3.05	$3.78	$3.01 ▼ $9.62	$219.14M	0.97	785,568 shs	677,625 shs
SLGL Sol-Gel Technologies	$88.00	$77.40	$13.50 ▼ $97.97	$247.28M	1.12	52,374 shs	46,380 shs
SPRO Spero Therapeutics	$1.26	$2.00	$1.08 ▼ $3.08	$72.95M	1.55	2.41 million shs	458,505 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	0.00%	+10.84%	+31.78%	+25.64%	+454.21%
SIGA Siga Technologies	0.00%	-6.73%	-15.04%	-32.97%	-65.96%
SLGL Sol-Gel Technologies	0.00%	+6.99%	+19.00%	+25.75%	+450.34%
SPRO Spero Therapeutics	0.00%	+7.69%	-40.00%	-50.59%	-42.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANTX Anthem	2.33	Hold	$9.00	51.77% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A
SLGL Sol-Gel Technologies	2.67	Moderate Buy	$197.50	124.43% Upside
SPRO Spero Therapeutics	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest SPRO, SIGA, SLGL, and ANTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	ANTX Anthem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/20/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
7/17/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	ANTX Anthem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
6/24/2026	SLGL Sol-Gel Technologies	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$285.00
6/15/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
6/4/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
5/29/2026	SLGL Sol-Gel Technologies	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
5/28/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
5/22/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Sell (D+)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
SIGA Siga Technologies	$94.57M	2.32	$0.33 per share	9.16	$2.78 per share	1.10
SLGL Sol-Gel Technologies	$19.39M	12.75	N/A	N/A	$8.19 per share	10.74
SPRO Spero Therapeutics	$66.80M	1.09	$0.15 per share	8.28	$1.05 per share	1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANTX Anthem	-$35.17M	-$1.10	N/A	N/A	N/A	N/A	-52.35%	-47.25%	N/A
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.51%	-1.25%	N/A
SLGL Sol-Gel Technologies	-$6.13M	-$0.34	N/A	N/A	N/A	-5.66%	-3.17%	-2.58%	8/21/2026 (Estimated)
SPRO Spero Therapeutics	$8.57M	$0.24	5.25	N/A	N/A	24.90%	35.58%	24.95%	8/12/2026 (Estimated)

Latest SPRO, SIGA, SLGL, and ANTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	N/A	N/A	N/A	$0.08 million	N/A
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	N/A	N/A	N/A	$0.28 million	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million
5/28/2026	Q1 2026	SLGL Sol-Gel Technologies	-$2.86	-$1.31	+$1.55	$1.31	$0.90 million	$0.11 million
5/13/2026	Q1 2026	SPRO Spero Therapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$0.26 million	$0.26 million
5/11/2026	Q1 2026	ANTX Anthem	-$0.23	-$0.29	-$0.06	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANTX Anthem	N/A	15.73	15.73
SIGA Siga Technologies	N/A	3.25	2.38
SLGL Sol-Gel Technologies	N/A	8.84	8.84
SPRO Spero Therapeutics	N/A	10.50	10.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANTX Anthem	90.47%
SIGA Siga Technologies	55.40%
SLGL Sol-Gel Technologies	26.18%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
ANTX Anthem	22.61%
SIGA Siga Technologies	2.73%
SLGL Sol-Gel Technologies	66.51%
SPRO Spero Therapeutics	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANTX Anthem	N/A	36.02 million	27.87 million	Not Optionable
SIGA Siga Technologies	40	71.85 million	69.89 million	Optionable
SLGL Sol-Gel Technologies	50	2.81 million	941,000	No Data
SPRO Spero Therapeutics	150	57.90 million	56.22 million	Optionable

SPRO, SIGA, SLGL, and ANTX Headlines

Recent News About These Companies

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 5, 2026 | globenewswire.com

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

August 4, 2026 | globenewswire.com

Spero Therapeutics (SPRO) Expected to Post Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?

August 4, 2026 | marketbeat.com

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

July 27, 2026 | globenewswire.com

Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below 200-Day Moving Average - Should You Sell?

July 25, 2026 | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average - Here's Why

July 17, 2026 | marketbeat.com

Spero Therapeutics inks major CD40L and royalty deals

July 16, 2026 | theglobeandmail.com

Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing

July 14, 2026 | seekingalpha.com

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

July 14, 2026 | reuters.com

Spero gets ex-China rights to Innovent’s antibody therapy for up to $1.1B

July 14, 2026 | msn.com

Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)

July 14, 2026 | finance.yahoo.com

Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029

July 14, 2026 | quiverquant.comQ

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

July 14, 2026 | globenewswire.com

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

July 14, 2026 | globenewswire.com

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

July 14, 2026 | prnewswire.com

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

July 8, 2026 | globenewswire.com

SPRO Share News Today

June 30, 2026 | uk.investing.com

Biggest stock movers Thursday: INTC, KR, ACN, and more

June 18, 2026 | seekingalpha.com

Spero shares jump after FDA clears first oral carbapenem antibiotic for US market (SPRO)

June 18, 2026 | msn.com

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

June 18, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SPRO, SIGA, SLGL, and ANTX Company Descriptions

Anthem NASDAQ:ANTX

$5.93 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$5.97 +0.04 (+0.67%)

As of 08/7/2026 07:34 PM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Siga Technologies NASDAQ:SIGA

$3.05 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$3.06 +0.02 (+0.49%)

As of 08:28 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Sol-Gel Technologies NASDAQ:SLGL

$88.00 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$87.56 -0.44 (-0.50%)

As of 06:18 AM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Spero Therapeutics NASDAQ:SPRO

$1.26 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.24 -0.02 (-1.59%)

As of 08:38 AM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRO, SIGA, SLGL, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRO, SIGA, SLGL, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRO, SIGA, SLGL, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SPRO, SIGA, SLGL, and ANTX Company Descriptions

Anthem NASDAQ:ANTX

Siga Technologies NASDAQ:SIGA

Sol-Gel Technologies NASDAQ:SLGL

Spero Therapeutics NASDAQ:SPRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRO, SIGA, SLGL, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRO, SIGA, SLGL, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRO, SIGA, SLGL, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SPRO, SIGA, SLGL, and ANTX Company Descriptions

Anthem NASDAQ:ANTX

Siga Technologies NASDAQ:SIGA

Sol-Gel Technologies NASDAQ:SLGL

Spero Therapeutics NASDAQ:SPRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools